Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa

NCT05537220 is registered in ClinicalTrials.gov with Johns Hopkins University as lead sponsor.

NCT NCT05537220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05537220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa
Lead sponsor
Johns Hopkins University
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 11, 2023
Completion date
May 31, 2030
Enrollment
485 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

retinitis pigmentosa